Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Sesen Bio, Inc. (SESN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.9129-0.0971 (-9.61%)
At close: 04:00PM EST
0.9200 +0.01 (+0.78%)
After hours: 07:49PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0100
Open1.0100
Bid0.9200 x 1400
Ask0.9286 x 1800
Day's Range0.9100 - 1.0120
52 Week Range0.7000 - 6.0400
Volume4,956,568
Avg. Volume15,502,179
Market Cap158.194M
Beta (5Y Monthly)0.50
PE Ratio (TTM)N/A
EPS (TTM)-0.8650
Earnings DateMay 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.25
  • InvestorPlace

    7 Penny Stocks with 10x Potential in 2022

    In recent months, the market’s appetite for penny stocks has been seriously curbed. This makes sense, given that cryptocurrencies have again become the risky plays favored by most retail speculators. Success in investing in sub-$5 stocks has become even more elusive. But that doesn’t mean you should skip out on the category completely. Why? Well, while few are trading at or near all-time highs right now, there are still scores of low-priced names that could see big spikes in the coming year. The

  • Business Wire

    Sesen Bio Strengthens Medical Team

    CAMBRIDGE, Mass., November 29, 2021--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the strengthening of its medical team with the hiring of Dominika Kowalski as Senior Director of Global Drug Safety. Ms. Kowalski’s hiring demonstrates Sesen Bio’s strong commitment to and continued focus on the development of Vicineum™ for the treatment of BCG-unresponsive non-muscle invasive bladd

  • Business Wire

    Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role

    CAMBRIDGE, Mass., November 23, 2021--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Jane Pritchett Henderson, previously a member of Sesen Bio’s Board of Directors and the Chair of the Board’s Audit Committee, has transitioned off the Board of Directors to a CEO Advisor role, effective November 22, 2021. Ms. Henderson departed the Board in order to concentrate on other respons

Advertisement
Advertisement